48218 Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices 

Potential applications of this 

technology may also include detection 

of Pax-2 protein in urine for both 

chronic and acute renal disease. 

Applications: Diagnostics for renal 

diseases; Research tools for evaluating 

disease processes of the kidney and 

other tissues through Pax-2 protein 

expression in the relevant tissues. 

Development Status: Ready for 

commercialization. 

Patent Status: HHS Reference No. B–

039–1996/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Inventor: Gregory Dressler (NICHD). 

Relevant Publications: 

1. GR Dressler. Another niche for 

Notch. Kidney Int. 2008 

Jun;73(11):1207–1209. 

2. SR Patel et al. The BRCT-domain 

containing protein PTIP links PAX2 to 

a histone H3, lysine 4 methyltransferase 

complex. Dev Cell. 2007 Oct;13(4):580–

592. 

3. GR Dressler. The cellular basis of 

kidney development. Annu Rev Cell 

Dev Biol. 2006;22:509–529. 

4. GB Silberstein et al. Expression of 

the PAX2 oncogene in human breast 

cancer and its role in progesteronedependent mammary growth. Oncogene. 

2002 Feb7;21(7):1009–1016. 

5. GR Dressler and AS Woolf. Pax2 in 

development and renal disease. Int J 

Dev Biol. 1999;43(5):463–468 (Review). 

6. GR Dressler. Pax-2, kidney 

development, and oncogenesis. Med 

Pediatr Oncol. 1996 Nov;27(5):440–444. 

7. GR Dressler and EC Douglass. Pax2 is a DNA-binding protein expressed in 

embryonic kidney and Wilms tumor. 

Proc Natl Acad Sci USA. 1992 Feb 

15;89(4):1179–1183. 

Licensing Status: Available for nonexclusive licensing as biological 

materials (internal use or commercial 

use). 

Licensing Contact: RC Tang, JD, LLM; 

301–435–5031; tangrc@mail.nih.gov. 

Dated: August 7, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–18983 Filed 8–19–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Species-Independent A3 Adenosine 

Receptor Agonists 

Description of Technology: The A3 

adenosine receptor (A3AR) subtype has 

been linked with helping protect the 

heart from ischemia, controlling 

inflammation, and regulating cell 

proliferation. Agonists of the human 

A3AR subtype have been described; 

however, they lack selectivity for the 

corresponding receptor of the mouse. 

This poses a problem for clinical 

development because animal model 

testing is important for pre-clinical 

validation of drug function. 

Consequently, a novel agonist was made 

that is selective for the mouse A3AR 

while retaining selectivity for the 

human receptor. This innovation should 

facilitate moving A3 agonists into the 

clinical phase of drug development with 

confidence. 

This invention claims speciesindependent agonists of A3AR, 

specifically (N)-methanocarba adenine 

nucleosides. In addition, it describes 

pharmaceutical compositions 

comprising such nucleosides, and 

methods of use such as administering an 

effective amount to a mammal. 

Applications: cardiac arrhythmias or 

ischemia; inflammation; stroke; 

diabetes; asthma; cancer. 

Market: Heart disease and cancer are 

the leading causes of death for both 

women and men in the United States 

despite many advances in drug 

development. Hence, there is a need for 

drugs with unique mechanism of action. 

It is noteworthy that the first synthetic 

adenosine receptor agonist has recently 

been approved for use in humans. 

Development Status: Research 

quantities of compounds have been 

synthesized and tested for receptor 

selectivity. 

Inventors: Kenneth A. Jacobson and 

Artem Melman (NIDDK). 

Publication: A Melman et al. Design 

of (N)-methanocarba adenosine 5′- 

uronamides as species-independent A3 

receptor-selective agonists. Bioorg Med 

Chem Lett. 2008 May 1;18(9):2813–

2819. 

Patent Status: U.S. Provisional 

Application No. 61/040,985 filed 31 Mar 

2008 (HHS Reference No. E–140–2008/ 

0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Norbert Pontzer, 

J.D., Ph.D.; 301–435–5502; 

pontzern@mail.nih.gov. 

Fluorescent Cell Lines for Detection of 

DNA Damage 

Description of Technology: The 

Enhanced Level of Genomic instability 

1 (ELG1) protein suppresses genomic 

instability caused by DNA damage. Cell 

lines for studying human ELG1 (hELG1) 

have been established that stably 

express a fusion protein combining 

hELG1 and either Green Fluorescent 

Protein (GFP) or Cyan Fluorescent 

Protein (CFP). It has been shown that 

the fluorescent hELG1 is an excellent 

reporter for DNA damage within the 

cell, with increased hELG1 localization 

to the cell nucleus upon exposure to a 

genotoxin. Therefore, these cell lines 

may have utility as a screening tool to 

detect genotoxic agents. 

Available for licensing are the RPE 

cell line (immortalized normal retinal 

pigment epithelial cells) stably 

expressing hELG1-CFP, and the U2OS 

cell line (human osteosarcoma cells) 

stably expressing hELG1-GFP. 

Applications: High-sensitivity 

screening tool for genotoxic agents. 

Inventor: Kyungjae Myung (NHGRI). 

Relevant Publication: In preparation. 

Patent Status: DHHS Reference No. E–

108–2008/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for nonexclusive licensing. 

Licensing Contact: Tara L. Kirby, 

Ph.D.; 301–435–4426; 

tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Chemical Genomics 

Center is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the assay for detection of 

genotoxic agents using RPE cell line 

having hELG1–CFP. Please contact 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 73, No. 160 / Monday, August 18, 2008 / Notices 48219 

Menghang Xia or James Inglese at 

mxia@mail.nih.gov or 

jinglese@mail.nih.gov for more 

information. 

August 7, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–18984 Filed 8–19–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(cX4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group; Cellular, 

Molecular and Integrative Reproduction 

Study Section. 

Date: September 15–16, 2008. 

Time: 8 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Mayflower Park Hotel, 405 Olive 

Way, Seattle, WA 98101. 

Contact Person: Stuart B. Moss, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6170, 

MSC 7892, Bethesda, MD 20892, 301–435–

1044, mossstua@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; CostEffectiveness Research. 

Date: September 16, 2008. 

Time: 10 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(telephone conference call). 

Contact Person: Elisabeth Koss, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3152, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1721, kosse@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Behavioral and Economic Evaluation 

of Medicare Part D. 

Date: September 19, 2008. 

Time: 9 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037. 

Contact Person: Valerie Durrant, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3148, 

MSC 7770, Bethesda, MD 20892, (301) 435–

3554, durrantv@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Stress, 

Fitness and Obesity. 

Date: September 29, 2008. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Michael Micklin, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3136, 

MSC 7759, Bethesda, MD 20892, (301) 435–

1258, micklinm@csr.nih.gov. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Biomedical 

Computing and Health Informatics Study 

Section. 

Date: October 2, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington DC/Rockville, 

1750 Rockville Pike, Rockville, MD 20852. 

Contact Person: Bill Bunnag, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5124, 

MSC 7854, Bethesda, MD 20892, (301) 435–

1177, bunnagb@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Neurobiology of 

Learning and Memory Study Section. 

Date: October 2–3, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037. 

Contact Person: Bernard F. Driscoll, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, 301–435–

1242, driscolb@csr.nih.gov. 

Name of Committee: Digestive Sciences 

Integrated Review Group; Gastrointestinal 

Cell and Molecular Biology Study Section. 

Date: October 2, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Express Fisherman’s 

Wharf, 550 North Point Street, San Francisco, 

CA 94133. 

Contact Person: Najma Begum, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2175, 

MSC 7818, Bethesda, MD 20892, 301–435–

1243, begumn@csr.nih.gov. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Adult Psychopathology and Disorders 

of Aging Study Section. 

Date: October 2–3, 2008. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Key Bridge Marriott, 1401 Lee 

Highway, Arlington, VA 22209. 

Contact Person: Alfonso R. Latoni, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3182, 

MSC 7848, Bethesda, MD 20892, 301–435–

0913, latonia@csr.nih.gov. 

Name of Committee: Health of the 

Population Integrated Review Group; 

Behavioral Genetics and Epidemiology Study 

Section. 

Date: October 2–3, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Palomar Washington, DC, 

2121 P Street, NW., Washington, DC 20037. 

Contact Person: Elisabeth Koss, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3152, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1721, kosse@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Neurotoxicology 

and Alcohol Study Section. 

Date: October 2, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Latham Hotel, 3000 M Street, NW., 

Washington, DC 20007. 

Contact Person: Brian Hoshaw, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5181, 

MSC 7844, Bethesda, MD 20892, 301–435–

1033, hoshawb@csr.nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Molecular 

Neuropharmacology and Signaling Study 

Section. 

Date: October 2–3, 2008. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Mayflower Park Hotel, 405 Olive 

Way, Seattle, WA 98101. 

Contact Person: Deborah L. Lewis, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4118, 

MSC 7850, Bethesda, MD 20892, 301–435–

1224, lewisdeb@csr.nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Molecular and 

Integrative Signal Transduction Study 

Section. 


sroberts on PROD1PC70 with NOTICES